Tom Livelli is the Vice President of Life Sciences at Promega Corporation, bringing with him over 35 years of experience in Molecular Cell Biology. Tom is responsible for the Pharma/Biotech and the Academic/Government market segments at Promega, working with the business teams to drive the strategy for these markets. Tom also manages Promega’s Elite Access business team (custom assay services), as well as the Strategic Collaboration Management Team (SCMT).
Prior to joining Promega, Tom was Vice President, Cellular Assay Systems and Collaborations Management at Invitrogen/Life Technologies Discovery Sciences. Before Invitrogen/Life Technologies, Tom was the President & CEO of Cell & Molecular Technologies Inc. (CMT), a biotechnology company he founded in 1997 and took public in 1998. CMT was acquired by Invitrogen in December, 2006.
Tom has done research in and managed the laboratory of Nobel Laureate Dr. Richard Axel at the Howard Hughes Medical Institute at Columbia University College of Physicians & Surgeons from 1986 to 1997. Tom’s research was focused on building cell-based assays to interrogate GPCR biology. Tom received his Bachelor of Arts degree in Biology from Columbia University in 1977.